SGLT2 Inhibitor Empagliflozin Is Shown to Be Safe | Newswise
Empagliflozin, an SGLT2 inhibitor, is safe and effective for treating heart attack patients, showing kidney-protective benefits and reducing heart failure events regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.
Related Clinical Trials
Highlighted Terms
Related News
Empagliflozin, an SGLT2 inhibitor, safely and effectively reduces heart failure events and confers kidney-protective benefits in patients hospitalized for acute myocardial infarction, regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.
Empagliflozin, an SGLT2 inhibitor, is safe and effective for treating heart attack patients, showing kidney-protective benefits and reducing heart failure events regardless of baseline kidney function, according to a Mount Sinai-led study presented at the European Society of Cardiology Congress.